SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

SNDL Inc.NASDAQ: SNDL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of CA$616K fell 55.6% year over year, behind the -20.8% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +12.9% a year.

Context

  • Stock-based compensation amounted to 1.5% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -55.6% toward the trailing-twelve-month pace of -20.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$616K+147.9% QoQ
Last fiscal yearDec 2025
CA$13.91M-30.6% YoY
LTMMar 2026
CA$13.13M-20.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-55.6%——
1 year-30.6%——
3-year CAGR+12.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CAD · from the cash flow

Latest · FY2025
13.91M CAD
Year-over-year change
-30.6%
4-year CAGR
+3.1%

Stock-Based Compensation vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -20.8% is the 9th highest of 11, against a peer median of +10.6%.
  • Stock-based compensation amounts to 1.4% of revenue for SNDL, versus a peer median of 3.8%.
SNDL Competitors
Stock-Based Compensation for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EOLSEvolus, Inc.LTM Mar 2026$19.89M USD-13.9%+24.1%6.6%
EBSEmergent BioSolutions Inc.LTM Mar 2026$16.6M USD+22.1%-28.9%2.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$13.57M USD+17.6%+26.6%2.6%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M USD-40.1%——
SNDLSNDL Inc.LTM Mar 2026CA$13.13M CAD-20.8%+12.9%1.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$12.76M USD+67.9%-14.2%5.5%
CMPSCOMPASS Pathways plcLTM Mar 2026$12.55M USD-31.5%+1.2%—
ESPREsperion Therapeutics, Inc.LTM Mar 2026$9.91M USD-11.7%-13.4%2.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$8.36M USD+17.6%+20.3%16.6%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M USD+88.8%+25.6%—
SIGASIGA Technologies, Inc.LTM Mar 2026$3.53M USD+3.6%+27.4%3.8%
Peer median (excluding SNDL) —+10.6%+20.3%3.8%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(230.18M)(372.43M)(176.55M)(96.2M)(15.77M)
Depreciation & Amortization9.6M47.32M64.95M56.71M56.27M
Deferred Income Tax(2.27M)(7.34M)0(9.41M)0
Stock-Based Compensation12.31M9.67M15.4M20.04M13.91M
Change in Working Capital(1.53M)(22.07M)(32.88M)(7.45M)1.43M
Accounts Receivables00000
Inventory16.98M7.01M000
Accounts Payables00000
Other Working Capital(18.51M)(29.09M)(32.88M)(7.45M)1.43M
Other Non-Cash Items56.64M338.14M112.43M91.22M15.08M
Operating Cash Flow(155.44M)(6.71M)(16.65M)54.91M70.92M
Capital Expenditures(3.79M)(10.86M)(7.93M)(11.02M)(12.81M)
Acquisitions (Net)(478.34M)(147.78M)(21.39M)(39.48M)(3M)
Purchases of Investments(24.21M)(75.6M)(732K)0(16.41M)
Sales of Investments10.68M00045.58M
Other Investing Activities(612K)4.07M5.15M65.85M4.1M
Investing Cash Flow(496.28M)(230.16M)(24.82M)17.76M17.45M
Debt Repayment(10.36M)(37.69M)(41.01M)(36.95M)(39.25M)
Common Stock Issued1.06B22K000
Common Stock Repurchased0(13.39M)(1.54M)(13.28M)(15.35M)
Dividends Paid00000
Other Financing Activities97.65M9.27M(531K)871K106K
Financing Cash Flow1.15B(41.79M)(43.08M)(49.36M)(54.49M)
Effect of Forex Changes(9K)0000
Net Change in Cash497.88M(278.67M)(84.55M)23.32M33.88M
Free Cash Flow(159.23M)(17.57M)(24.58M)43.9M58.11M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.